GenoMed, Inc. Announces Drug Therapy to Avoid Dialysis in Acute Kidney Failure
ST. LOUIS, Aug. 13 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed), a St. Louis, Missouri-based medical genomics biotechnology company, announced today a new drug treatment based on pilot data that avoids dialysis in the setting of acute kidney failure.
Based on pilot data conducted by Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, the drug regimen avoided the need for dialysis in over 80% of adults in the hospital with acute kidney failure. This drug regimen has also been used with similar success for neonates with acute kidney failure in the Neonatal Intensive Care Unit. The same treatment should be useful in avoiding non-function of transplanted kidneys after harvesting from donors and immediately after placement into recipients.
Dr. Moskowitz gave the patients a loading dose and an infusion of an already existing medication, aminophylline. This specific treatment has not been used before, and is based on the physiology of why the kidney shuts down in acute kidney failure. On August 8, 2001, Genomed filed its first application for world-wide patent protection involving aminophylline in acute kidney failure.
"Despite the introduction of kidney dialysis within the past 50 years," says Dr. Moskowitz, "acute kidney failure is still associated with a 50% mortality rate. It is a devastatingly expensive problem for all concerned. Avoiding dialysis may be the first step towards reducing the costs and mortality of acute kidney failure. This treatment should also be especially useful in settings without ready access to kidney dialysis machines, such as third-world hospitals or disaster sites such as earthquakes."
Dr. Moskowitz, a nephrologist trained at Harvard, Oxford and Washington University in St. Louis, was formerly a staff physician at the St. Louis VA Medical Center and assistant professor at Saint Louis University School of Medicine. "The mission of GenoMed is to serve as a Next Generation Disease Management(TM) company, translating insights about how disease is caused into better treatments for patients," Dr. Moskowitz said. "We have compelling data that is immediately valuable to patients, their physicians, and health care payers, and which offers immediate cost savings."
About GenoMed
GenoMed is a biotech company based in St. Louis, Missouri, that is working to translate knowledge of disease pathways into better patient outcomes as rapidly and safely as possible. Building on its initial discoveries and success, GenoMed is dedicated to (1) identifying additional disease-associated genes and pathways; (2) working on new treatments using existing drugs whenever possible; and, (3) developing new drugs when necessary to stop disease-causing pathways. GenoMed's stock ticker symbol is GMED.
For additional information, please visit www.genomedics.com and/or contact Krissy Fischer at 1-877-GENOMED or e-mail at kfischer@genomedics.com for additional written information pertaining to GenoMed.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
kfischer@genomedics.com
Web site: genomedics.com
. |
